Precigen's OS Therapies Strengthens Leadership for FDA Engagement on Cancer Immunotherapy

### Strategic Board Appointments Strengthen OS Therapies' Path to FDA Engagement

OS Therapies, a clinical-stage biopharmaceutical company focused on immunotherapy and Antibody Drug Conjugates, enhances its leadership team with the recent appointment of Avril McKean Dieser and Olivier R. Jarry to its Board of Directors. With a combined experience exceeding 50 years in the biopharmaceutical sector, their expertise is particularly relevant as OS Therapies prepares to engage with the FDA regarding a pivotal clinical trial for its promising cancer immunotherapy, OST-HER2. This drug targets resected, recurrent osteosarcoma, aiming to prevent metastasis in patients—a crucial step in addressing an aggressive form of bone cancer.

The appointment of McKean Dieser, who brings extensive experience in regulatory affairs, pricing, and commercialization, is particularly strategic. Currently serving as Vice President and Head of Legal Patient Evidence at UCB, Inc., her background includes significant roles at AbbVie Inc. and an understanding of the regulatory landscape that will be vital as OS Therapies seeks to navigate the complexities of FDA approvals. Additionally, her personal connection to osteosarcoma, having lost her son to the disease, adds a layer of commitment and urgency to her role, reflecting the company's mission to make impactful advancements in cancer treatment.

Olivier R. Jarry, with his background in business development and fundraising, complements McKean Dieser's regulatory expertise. His experience will be instrumental in securing strategic partnerships that could facilitate OS Therapies' international market access. CEO Paul Romness emphasizes that these board additions symbolize a proactive approach to building an internal infrastructure geared towards regulatory approval and commercial launch in the United States. This dual focus on strong leadership and strategic partnerships positions OS Therapies favorably as it embarks on this critical phase of development.

In addition to the board appointments, OS Therapies acknowledges the contributions of outgoing members Dr. Colin Goddard and Mr. Joacim Borg during the company's transition to a public entity. Their efforts laid the groundwork for the company’s current initiatives and future aspirations. As OS Therapies moves forward, the integration of these new perspectives may prove vital in navigating the challenges of bringing innovative therapies to the market.

OS Therapies' commitment to addressing unmet medical needs in oncology, coupled with its strengthened leadership team, reflects a promising trajectory for the company. The combination of regulatory acumen and business development prowess may accelerate its journey toward impactful cancer treatments, especially for patients facing the challenges of osteosarcoma.